Cargando…
Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature
BACKGROUND: The optimal first-line chemotherapy for ovarian carcinosarcoma has not yet been determined. We therefore sought to determine the progression-free survival (PFS) and overall survival (OS) for patients with ovarian carcinosarcoma treated at our institution with different first-line chemoth...
Autores principales: | Brackmann, Melissa, Stasenko, Marina, Uppal, Shitanshu, Erba, Jake, Reynolds, R. Kevin, McLean, Karen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810191/ https://www.ncbi.nlm.nih.gov/pubmed/29426293 http://dx.doi.org/10.1186/s12885-018-4082-6 |
Ejemplares similares
-
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
por: Nishikawa, Tadaaki, et al.
Publicado: (2017) -
Overall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma: A Single-Institution Experience
por: Nizam, Aaron, et al.
Publicado: (2019) -
Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
por: Jernigan, Amelia M., et al.
Publicado: (2013) -
Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
por: Coffman, Lan G., et al.
Publicado: (2022) -
Ovarian Carcinosarcoma and Response to Immunotherapy
por: Daniyal, Muhammad, et al.
Publicado: (2023)